ストックスクリーナーアプリを入手
45.49
1.32%
-0.61
アフターアワーズ：
45.49
前日終値:
$46.10
開ける：
$45.2
24時間の取引高:
1.35M
Relative Volume:
0.72
時価総額：
$7.63B
収益：
$1.56B
当期純損益:
$152.72M
株価収益率:
50.58
EPS:
0.8994
ネットキャッシュフロー:
$221.80M
1週間 パフォーマンス:
-3.62%
1か月 パフォーマンス:
-7.48%
6か月 パフォーマンス:
+58.89%
1年 パフォーマンス:
+59.89%
1日の値動き範囲:
$44.63
$46.53
1週間の範囲:
$44.63
$48.73
52週間の値動き範囲:
$26.40
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
45.49 | 7.73B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
18.32 | 58.92B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.76 | 42.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.25 | 42.22B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.56 | 31.33B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
497.97 | 20.91B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-29 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews
Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st
Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus
Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan
Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa
Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com India
Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews
Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail
Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus
Rising Star: Goodwin's Heath Ingram - Law360
ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus
Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria
Alkermes narcolepsy drug shows positive phase 2 trial results - Investing.com
Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade
Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade
Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn
Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus
Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat
STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus
Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus
Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan
Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet
Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews
Alkermes (ALKS) Eases to $49.06: Key Levels to Watch After 0.79% DipPrice Target - Vinanet
S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat
Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat
Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat
Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView
Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media
Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria
Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada
Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView
Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan
Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com
Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance
Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st
The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat
Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat
(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amundi Increases Stake in Alkermes plc $ALKS - MarketBeat
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
0.75%
2.12%
大文字化:
|
ボリューム (24 時間):